Wechselwirkungen von Vitamin K

Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (Fachinformation zu Butalbital, Acetylsalicylsäure und Koffein, Gegenanzeigen)

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (Fachinformation zu Capecitabin, Boxed Warning (umrahmter Warnhinweis))

Do not administer agents that enhance the risk of hemorrhage with fondaparinux sodium unless essential for the management of the underlying condition, such as vitamin K antagonists for the treatment of VTE. (Fachinformation zu Fondaparinux, Warnhinweise und Vorsichtsmaßnahmen)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (Fachinformation zu Fosphenytoin, Warnhinweise und Vorsichtsmaßnahmen)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (Fachinformation zu Phenytoin, Warnhinweise und Vorsichtsmaßnahmen)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (Fachinformation zu Rifampicin, Warnhinweise)

Vitamin K verringert die gerinnungshemmende Wirkung von Warfarin; plötzliche Änderungen der Zufuhr über Nahrungsergänzungsmittel oder die Ernährung können den INR-Wert aus dem Gleichgewicht bringen. (NIH Office of Dietary Supplements, Vitamin K)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (Fachinformation zu Apixaban, Warnhinweise und Vorsichtsmaßnahmen)

Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (Fachinformation zu Bicalutamid, Warnhinweise und Vorsichtsmaßnahmen)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (Fachinformation zu Butalbital, Acetylsalicylsäure, Koffein und Codein, Warnhinweise und Vorsichtsmaßnahmen)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (Fachinformation zu Cefepim, Warnhinweise und Vorsichtsmaßnahmen)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (Fachinformation zu Cefixim, Warnhinweise und Vorsichtsmaßnahmen)

Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (Fachinformation zu Cefotetan, Warnhinweise)

Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (Fachinformation zu Ceftriaxon, Warnhinweise und Vorsichtsmaßnahmen)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (Fachinformation zu Chinin, Arzneimittelwechselwirkungen)

Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (Fachinformation zu Colesevelam, Warnhinweise und Vorsichtsmaßnahmen)

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (Fachinformation zu Dabigatran, Warnhinweise und Vorsichtsmaßnahmen)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (Fachinformation zu Edoxaban, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (Fachinformation zu Neomycin, Arzneimittelwechselwirkungen)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Fachinformation zu Orlistat, Arzneimittelwechselwirkungen)

Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (Fachinformation zu Propylthiouracil, Arzneimittelwechselwirkungen)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (Fachinformation zu Rivaroxaban, Warnhinweise und Vorsichtsmaßnahmen)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (Fachinformation zu Sugammadex, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (Fachinformation zu Thiamazol, Arzneimittelwechselwirkungen)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (Fachinformation zu Methylergometrin, Warnhinweise)

Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (Fachinformation zu Phytomenadion (Vitamin K1), Warnhinweise und Vorsichtsmaßnahmen)

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (Fachinformation zu Primidon, Warnhinweise)